Skip to content

Clinical study of Penehyclidine for prevention of postoperative nausea and vomiting following general anesthesia

Clinical study of Penehyclidine for prevention of postoperative nausea and vomiting following general anesthesia

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300069082
Enrollment
Unknown
Registered
2023-03-06
Start date
2023-04-01
Completion date
Unknown
Last updated
2023-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Interventions

A Group:the moumal salinegroup
B Group:Injection of 0.5 mg Penehyclidine before induction of anesthesia.
C Group:I.V 0.25mg Penehyclidine before anesthesia induction, and 0.25mg Penehyclidine was added to the postoperative intravenous analgesia pump.

Sponsors

The Second People's Hospital of Changzhou
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1) Patients have a strong desire for surgery, and the weight loss effect by diet and exercise is not ideal.2) Age from 18 to 65 years old, and received LSG for the first time. 3) BMI from 32 to 50. 4) ASA grade from ?to ?,and can tolerate general anesthesia and laparoscopic surgery.

Exclusion criteria

Exclusion criteria: 1). Glaucoma and prostate hypertrophy patients; 2). Allergic to Penehyclidine, atropine,or other anticholindrugs. 3). Antiemetic treatment within 12 hours before surgery; 4). History of schizophrenia, Parkinson's disease, deep dementia, or language disorder; 5). ASA is equal or greater than IV. 6). Patients with severe liver and kidney insufficiency; 7). Patients with a history of gastrointestinal diseases or surgery, or those who are breastfeeding during pregnancy; 8). Patients have poor compliance and cannot cooperate with preoperative preparation and postoperative rehabilitation guidance; 9). Patients considered unsuitable for participation according to the investigators judgment were also excluded.

Design outcomes

Primary

MeasureTime frame
Severity of the PONV;

Countries

China

Contacts

Public ContactWu Zhouquan

The Second People's Hospital of Changzhou

wuzhouquan2005@126.com13861023270

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026